205 related articles for article (PubMed ID: 17438105)
1. A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy.
Leja J; Dzojic H; Gustafson E; Oberg K; Giandomenico V; Essand M
Clin Cancer Res; 2007 Apr; 13(8):2455-62. PubMed ID: 17438105
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
3. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
4. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
5. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
[TBL] [Abstract][Full Text] [Related]
6. Telomerase-dependent oncolytic adenovirus for cancer treatment.
Huang TG; Savontaus MJ; Shinozaki K; Sauter BV; Woo SL
Gene Ther; 2003 Aug; 10(15):1241-7. PubMed ID: 12858189
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
[TBL] [Abstract][Full Text] [Related]
8. Gene expression in intrahepatic tumors through DNA recombination by a replication-activated adenovirus vector.
Huang XW; Lieber A; Tang ZY; Lawrence TS; Moyer MP; Zhang M
Cancer Gene Ther; 2004 Jun; 11(6):450-6. PubMed ID: 15073612
[TBL] [Abstract][Full Text] [Related]
9. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
Melquist JJ; Kacka M; Li Y; Malaeb BS; Elmore J; Baseman AG; Hsieh JT; Koeneman KS
Urol Oncol; 2006; 24(4):362-71. PubMed ID: 16818192
[TBL] [Abstract][Full Text] [Related]
10. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
11. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
Cho WK; Seong YR; Lee YH; Kim MJ; Hwang KS; Yoo J; Choi S; Jung CR; Im DS
Mol Ther; 2004 Nov; 10(5):938-49. PubMed ID: 15509511
[TBL] [Abstract][Full Text] [Related]
13. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.
Fukuda K; Abei M; Ugai H; Seo E; Wakayama M; Murata T; Todoroki T; Tanaka N; Hamada H; Yokoyama KK
Cancer Res; 2003 Aug; 63(15):4434-40. PubMed ID: 12907616
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
Maemondo M; Saijo Y; Narumi K; Kikuchi T; Usui K; Tazawa R; Matsumoto K; Nakamura T; Sasaki K; Takahashi M; Niitsu Y; Nukiwa T
Cancer Res; 2004 Jul; 64(13):4611-20. PubMed ID: 15231673
[TBL] [Abstract][Full Text] [Related]
15. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
[TBL] [Abstract][Full Text] [Related]
16. A truncated minimal-E1a gene with potency to support adenoviral replication mediates antitumor activity by down-regulating Neu expression and preserving Rb function.
Fang L; Huang Y; Hu X; Sun L; He X; Hu H; Pu Y; Cao X; Luo H; Pan S; Gu J; Su C
Chem Biol Interact; 2009 Sep; 181(1):1-7. PubMed ID: 19523934
[TBL] [Abstract][Full Text] [Related]
17. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
[TBL] [Abstract][Full Text] [Related]
18. A cancer terminator virus eradicates both primary and distant human melanomas.
Sarkar D; Su ZZ; Park ES; Vozhilla N; Dent P; Curiel DT; Fisher PB
Cancer Gene Ther; 2008 May; 15(5):293-302. PubMed ID: 18323853
[TBL] [Abstract][Full Text] [Related]
19. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
Shirakawa T; Hamada K; Zhang Z; Okada H; Tagawa M; Kamidono S; Kawabata M; Gotoh A
Clin Cancer Res; 2004 Jul; 10(13):4342-8. PubMed ID: 15240520
[TBL] [Abstract][Full Text] [Related]
20. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
Zhu M; Bristol JA; Xie Y; Mina M; Ji H; Forry-Schaudies S; Ennist DL
J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]